This AAN meeting is the most important congress to present results from a new Parkinsonian drug like ATH434. Instead of Stamler, it is Claassen who makes this presentation. However, the first name on the poster is Stamler. So, there is a reason why Claassen presents the results of the 201 study.
I hope the reason is that Stamler is busy negotiating a deal with big pharma. It is not, however, the most likely reason. I hope he is not sick. But, sure, Claassen is IMO a very good presenter. He is also a clinical professor in neurology, so he may answer the possible clinical questions more fluently (?). He has been dealing with the open-label 202 study a lot, and he has a lot of experience in treating MSA patients even earlier. In any case looks like Stamler wants Claassen to present the most important paper of ATH ever.
ATH Price at posting:
0.7¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)